Abstract
Pituitary adenomas are a common benign neoplasm of the brain estimated to represent approximately 15–20% of all intracranial neoplasms. Clinically nonfunctioning pituitary adenomas account for 25–30% of pituitary adenomas, while secreting pituitary adenomas account for the rest. Pituitary adenomas are found incidentally on brain computed tomography (CT) or magnetic resonance imaging (MRI) scans in approximately 20–40% of cases. Other patients present with visual symptoms from tumor compression of the optic chiasm, headache, or hypopituitarism. Secreting adenomas often present with symptoms related to hormone hypersecretion. Treatment of pituitary adenomas can include a combination of medical management, surgical resection, and radiation therapy. Radiation is typically reserved for subtotal resections, recurrence, secreting pituitary adenomas refractory to surgery and medical management, and atypical pituitary adenomas. When radiation therapy is needed for nonfunctional pituitary adenomas, fractionated doses of 45–50.4 Gray (Gy) and radiosurgery doses of 15 Gy should be used. Secreting pituitary adenomas require higher doses, either 50.4–54 Gy for a fractionated course or at least 20 Gy for stereotactic radiosurgery (SRS). Radiation therapy provides excellent 10-year local control rates approaching 90–95%.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62.
Gittleman H, Ostrom QT, Farah PD, et al. Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. J Neurosurg. 2014;121(3):527–35.
Mehta GU, Lonser RR. Management of hormone-secreting pituitary adenomas. Neuro Oncol. 2017;19(6):762–73.
Schoemaker MJ, Swerdlow AJ. Risk factors for pituitary tumors: a case-control study. Cancer Epidemiol Biomark Prev. 2009;18(5):1492–500.
Caimari F, Korbonits M. Novel genetic causes of pituitary adenomas. Clin Cancer Res. 2016;22(20):5030–42.
Vasilev V, Rostomyan L, Daly AF, et al. MANAGEMENT OF ENDOCRINE DISEASE: Pituitary ‘incidentaloma’: neuroradiological assessment and differential diagnosis. Eur J Endocrinol. 2016;175(4):R171–84.
Paschou S, Vryonidou A, Goulis DG. Pituitary incidentalomas: a guide to assessment, treatment and follow-up. Maturitas. 2016;92:143–9.
Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin N Am. 2008;37(1):151–71, xi.
Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary. 2010;13(2):123–9.
Ouyang T, Rothfus WE, Ng JM, et al. Imaging of the pituitary. Radiol Clin N Am. 2011;49(3):549–71, vii.
DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumors. Pathology and genetics of tumours of endocrine organs. Lyon: IARC; 2004.
Kovacs K, Horvath E, Vidal S. Classification of pituitary adenomas. J Neurooncol. 2001;54(2):121–7.
Wilson CB. A decade of pituitary microsurgery. The Herbert Olivecrona lecture. J Neurosurg. 1984;61(5):814–33.
Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33(4):610–7; discussion 7–8.
Micko AS, Wohrer A, Wolfsberger S, et al. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 2015;122(4):803–11.
Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301–42.
Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509–17.
Chole RA, Lim C, Dunham B, et al. A novel transnasal transsphenoidal speculum: a design for both microscopic and endoscopic transsphenoidal pituitary surgery. J Neurosurg. 2011;114(5):1380–5.
Pomeraniec IJ, Dallapiazza RF, Xu Z, et al. Early versus late Gamma Knife radiosurgery following transsphenoidal resection for nonfunctioning pituitary macroadenomas: a matched cohort study. J Neurosurg. 2016;125(1):202–12.
Erturk E, Tuncel E, Kiyici S, et al. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary. 2005;8(2):93–7.
Yamada S, Fukuhara N, Horiguchi K, et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg. 2014;121(6):1462–73.
Platta CS, Mackay C, Welsh JS. Pituitary adenoma: a radiotherapeutic perspective. Am J Clin Oncol. 2010;33(4):408–19.
Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27(5):485–534.
Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17(6):610–38.
Schteingart DE. Drugs in the medical treatment of Cushing’s syndrome. Expert Opin Emerg Drugs. 2009;14(4):661–71.
Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3888–921.
Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab. 2008;93(10):3717–26.
Sadik ZH, Voormolen EH, Depauw PR, et al. Treatment of non-functional pituitary adenoma post-operative remnants: adjuvant or delayed gamma knife radiosurgery? World Neurosurg. 2017;100:361.
Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951;102(4):316–9.
Lamba M, Breneman JC, Warnick RE. Evaluation of image-guided positioning for frameless intracranial radiosurgery. Int J Radiat Oncol Biol Phys. 2009;74(3):913–9.
Guckenberger M, Baier K, Guenther I, et al. Reliability of the bony anatomy in image-guided stereotactic radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys. 2007;69(1):294–301.
Loeffler JS, Shih HA. Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 2011;96(7):1992–2003.
Liao HI, Wang CC, Wei KC, et al. Fractionated stereotactic radiosurgery using the Novalis system for the management of pituitary adenomas close to the optic apparatus. J Clin Neurosci. 2014;21(1):111–5.
Killory BD, Kresl JJ, Wait SD, et al. Hypofractionated CyberKnife™ radiosurgery for perichiasmatic pituitary adenomas: early results. Neurosurgery. 2009;64(2 Suppl):A19.
Vladyka V, Liscak R, Novotny J Jr, et al. Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery. 2003;52(2):309–16; discussion 16–7.
Pai HH, Thornton A, Katznelson L, et al. Hypothalamic/pituitary function following high-dose conformal radiotherapy to the base of skull: demonstration of a dose-effect relationship using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;49(4):1079–92.
Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.
Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.
Anker CJ, Shrieve DC. Basic principles of radiobiology applied to radiosurgery and radiotherapy of benign skull base tumors. Otolaryngol Clin N Am. 2009;42(4):601–21.
Sheehan JP, Xu Z, Salvetti DJ, et al. Results of gamma knife surgery for Cushing’s disease. J Neurosurg. 2013;119(6):1486–92.
Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab. 2009;5(2):88–99.
Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. Int J Radiat Oncol Biol Phys. 1993;27(2):215–21.
Minniti G, Osti MF, Niyazi M. Target delineation and optimal radiosurgical dose for pituitary tumors. Radiat Oncol. 2016;11(1):135.
Patel TR, Chiang VL. Secondary neoplasms after stereotactic radiosurgery. World Neurosurg. 2014;81(3–4):594–9.
Erridge SC, Conkey DS, Stockton D, et al. Radiotherapy for pituitary adenomas: long-term efficacy and toxicity. Radiother Oncol. 2009;93(3):597–601.
Bir SC, Murray RD, Ambekar S, et al. Clinical and radiologic outcome of gamma knife radiosurgery on nonfunctioning pituitary adenomas. J Neurol Surg B Skull Base. 2015;76(5):351–7.
Laws ER, Sheehan JP, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol. 2004;69(1–3):257–72.
Brada M, Ashley S, Ford D, et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol. 2002;57(6):713–7.
Sattler MG, Vroomen PC, Sluiter WJ, et al. Incidence, causative mechanisms, and anatomic localization of stroke in pituitary adenoma patients treated with postoperative radiation therapy versus surgery alone. Int J Radiat Oncol Biol Phys. 2013;87(1):53–9.
Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90(2):800–4.
Minniti G, Scaringi C, Poggi M, et al. Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol. 2015;172(4):433–41.
Diallo AM, Colin P, Litre CF, et al. Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly. Endocrine. 2015;50(3):741–8.
Puataweepong P, Dhanachai M, Hansasuta A, et al. Outcomes for pituitary adenoma patients treated with Linac-based stereotactic radiosurgery and radiotherapy: a long term experience in Thailand. Asian Pac J Cancer Prev. 2015;16(13):5279–84.
Kopp C, Theodorou M, Poullos N, et al. Fractionated stereotactic radiotherapy in the treatment of pituitary adenomas. Strahlenther Onkol. 2013;189(11):932–7.
Kim JO, Ma R, Akagami R, et al. Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency. Int J Radiat Oncol Biol Phys. 2013;87(3):528–33.
Wilson PJ, De-Loyde KJ, Williams JR, et al. A single centre’s experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the Linear Accelerator (Linac). J Clin Neurosci. 2012;19(3):370–4.
Sun DQ, Cheng JJ, Frazier JL, et al. Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature. Neurosurg Rev. 2010;34(2):181–9.
Schalin-Jantti C, Valanne L, Tenhunen M, et al. Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5.25-year follow-up study. Clin Endocrinol. 2010;73(1):72–7.
Iwata H, Sato K, Tatewaki K, et al. Hypofractionated stereotactic radiotherapy with CyberKnife™ for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro Oncol. 2011;13(8):916–22.
Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol. 1993;38(6):571–8.
Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008;108(4):736–45.
Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab. 2006;91(4):1239–45.
Milker-Zabel S, Zabel A, Huber P, et al. Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma. Int J Radiat Oncol Biol Phys. 2004;59(4):1088–96.
Estrada J, Boronat M, Mielgo M, et al. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing’s disease. N Engl J Med. 1997;336(3):172–7.
Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neurooncol. 2007;84(1):79–84.
Brucker-Davis F, Oldfield EH, Skarulis MC, et al. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84(2):476–86.
Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148(4):433–42.
Li X, Li Y, Cao Y, et al. Safety and efficacy of fractionated stereotactic radiotherapy and stereotactic radiosurgery for treatment of pituitary adenomas: a systematic review and meta-analysis. J Neurol Sci. 2017;372:110–6.
Sheehan JP, Starke RM, Mathieu D, et al. Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013;119(2):446–56.
Starke RM, Williams BJ, Jane JA Jr, et al. Gamma Knife surgery for patients with nonfunctioning pituitary macroadenomas: predictors of tumor control, neurological deficits, and hypopituitarism. J Neurosurg. 2012;117(1):129–35.
Park KJ, Kano H, Parry PV, et al. Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas. Neurosurgery. 2011;69(6):1188–99.
Franzin A, Spatola G, Losa M, et al. Results of gamma knife radiosurgery in acromegaly. Int J Endocrinol. 2012;2012:342034.
Sheehan J, Pouratian N, Steiner L, et al. Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg. 2011;114(2):303–9.
Minniti G, Clarke E, Scaringi C, et al. Stereotactic radiotherapy and radiosurgery for non-functioning and secreting pituitary adenomas. Rep Pract Oncol Radiother. 2016;21(4):370–8.
Amichetti M, Amelio D, Minniti G. Radiosurgery with photons or protons for benign and malignant tumours of the skull base: a review. Radiat Oncol. 2012;7:210.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Burt, L.M., Suneja, G., Shrieve, D.C. (2018). Pituitary Adenoma. In: Chang, E., Brown, P., Lo, S., Sahgal, A., Suh, J. (eds) Adult CNS Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42878-9_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-42878-9_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42877-2
Online ISBN: 978-3-319-42878-9
eBook Packages: MedicineMedicine (R0)